Velindre NHS Trust
17
2
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
18%
3 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Role: collaborator
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
Role: lead
Volatile Organic Compounds as Breath Biomarkers in Squamous Oesophageal Neoplasms
Role: collaborator
Cancer Loyalty Card Study
Role: collaborator
Virtual Reality for Advanced Cancer Pain
Role: collaborator
MEK and MET Inhibition in Colorectal Cancer
Role: collaborator
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Role: lead
Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
Role: collaborator
18F-FDG-PET Guided Dose-Painting With Intensity Modulated Radiotherapy in Oropharyngeal Tumours
Role: collaborator
PEARL PET-based Adaptive Radiotherapy Clinical Trial
Role: lead
Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients
Role: lead
CRT Hydration in the Last Days of Life (Feasibility Study)
Role: collaborator
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
Role: lead
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Role: lead
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
Role: collaborator
A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
Role: collaborator
Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
Role: lead
All 17 trials loaded